# 1 **Drivers underpinning the malignant transformation of giant cell**

## 2 **tumour of bone**

- 3 Matthew W. Fittall<sup>1,2,3</sup>, Peter Ellery<sup>2,4</sup>, Iben Lyskjær<sup>2</sup>, Patrick Lombard<sup>2</sup>, Jannat Ijaz<sup>3</sup>,
- 4 Anna-Christina Strobl<sup>4</sup>, Dahmane Oukrif<sup>2</sup>, Maxime Tarabichi<sup>1,3</sup>, Martin Sill<sup>5,6</sup>,
- 5 Christian Koelsche<sup>6,7</sup>, Jonas Demeulemeester<sup>1,8</sup>, Grace Collord<sup>3</sup>, Roberto
- 6 Tirabosco<sup>4</sup>, Fernanda Amary<sup>4</sup>, Peter J. Campbell<sup>3</sup>, Stefan Pfister<sup>6,7</sup>, David T.W.
- 7 Jones<sup>6,7</sup>, Nischalan Pillay<sup>2,4</sup>, Peter Van Loo<sup>1,8</sup>, Sam Behjati<sup>#3,9</sup>, Adrienne M.
- 8 Flanagan $*2,4$
- 9 <sup>#</sup>These authors jointly directed and contributed equally to this research.

## 10 **Affiliations**

- 11 <sup>1</sup> The Francis Crick Institute, London, NW1 1AT, UK
- <sup>2</sup> University College London Cancer Institute, London, WC1E 6DD, UK
- 13 <sup>3</sup>Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- 14 <sup>4</sup> Department of Histopathology, Royal National Orthopaedic Hospital NHS Trust,
- 15 Stanmore, UK
- <sup>5</sup> Division of Biostatistics, German Cancer Research Center (DKFZ), 69120
- 17 Heidelberg, Germany
- 18 <sup>6</sup> Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and
- 19 German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
- <sup>7</sup> Department of Neuropathology, Institute of Pathology, University Hospital
- 21 Heidelberg, 69120 Heidelberg, Germany
- 22 <sup>8</sup> Department of Human Genetics, University of Leuven, Leuven, Belgium
- 23 <sup>9</sup> Department of Paediatrics, University of Cambridge, Cambridge, CB2 0QQ, UK
- 24 Correspondence and requests for material should be directed to S.B. (email:
- 25 sb31@sanger.ac.uk) and A.M.F. (email: a.flanagan@ucl.ac.uk)

# 26 **Drivers underpinning the malignant transformation of giant cell**  27 **tumour of bone**

**The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique G34W oncohistone mutation in the H3.3 histone gene. Here we reveal the genomic and methylation patterns underlying the rare clinical phenomena of benign metastases and malignant transformation of GCTB.** 

32 Giant cell tumour of bone (GCTB) is a locally destructive benign tumour, prone to

33 local recurrence. They present predominantly at the site of the mature

34 epiphysis/epimetaphysis of the long bones, particularly the distal femur and proximal

35 tibia in the 3<sup>rd</sup> and 4<sup>th</sup> decades of life<sup>1</sup>. GCTB is defined by a near universal (96%)

36 pathognomonic H3F3A G34W missense mutation $^{2-6}$ . Two unexplained phenomena

37 in GCTB are of particular interest, namely that lung metastases occur despite the

38 absence of malignant histological features in either the primary or metastatic lesions<sup>7</sup>

39 and secondly that the characteristic H3.3 mutation is occasionally found in primary

40 malignant bone tumours which often share features with conventional GCTB<sup>4,8</sup>. We

41 set out to explore the genomic events underlying these phenomena using whole

42 genome sequencing and genome-wide methylation profiling using methylation array

43 and whole genome bisulfite sequencing.

44 We started our investigation by performing whole genome sequencing (WGS) on 45 seven primary malignant bone tumours possessing an H3.3 mutation, one case of 46 metastatic GCTB, and nine conventional GCTB for which we had frozen tissue with 47 corresponding germline DNA from blood samples (**Supplementary Table 1)**. We 48 used the analysis pipeline of the *Cancer Genome Project* to generate catalogues of

2<br>2

49 somatic mutations, indels, structural variants and copy number changes and a

50 previously reported strategy to identify putative drivers (**Methods**)<sup>9</sup>.



61 **Supplementary Figure 1**).

62 Unlike osteosarcoma, malignant H3.3-mutated bone tumours are enriched with 63 mutations suggesting telomere dysfunction. Two tumours had mono-allelic G>A 64 mutations 124bp upstream of the *TERT* transcription start site, reported to increase 65 promoter binding<sup>10</sup>. Another sample, PD3788d, had a complex rearrangement event, 66 resembling chromothripsis, encompassing *TERT,* resulting in the juxtaposition of the 67 gene *MEGF10* with the *TERT* promoter (**Supplementary Figure 2**). *MEGF10* is 68 reported to be under the control of a super-enhancer in the dbSUPER database<sup>11</sup>. 69 Two other malignant samples, PD4922e and PD30985a, were identified as having 70 markedly elongated telomeres (**Figure 1b, Supplementary Figure 1** and **Methods**), 71 a finding consistent with the Alternative Lengthening of Telomeres (ALT) 72 mechanism, which is usually mutually exclusive with *TERT* alteration<sup>12,13</sup>. In keeping



91 We next investigated the 'benign metastasising GCTB<sup>'1</sup>. In contrast to malignant 92 tumours, the morphology of both the metastases and primary lesion (PD38329a/c/d) 93 was that of a conventional GCTB which was reflected in the low mutational burden 94 and the absence of additional driver mutations (**Figure 1b and Supplementary**  95 **Figure 1**). Leveraging the independent sampling across these three tumour samples 96 increased the power to define the clonality of mutations. Clonal mutations are those

97 found in all tumours cells whereas those in only a fraction of cells are considered 98 subclonal. The primary tumour (PD38329a) and the two metastases (PD38329c and 99 PD38329d) each possessed a group of private mutations to only that tumour sample. 100 Furthermore, one cluster of mutations (**Supplementary Figure 6)** was found to be 101 common but subclonal in all samples. This suggests that both metastases were 102 seeded by at least one cell possessing those mutations and at least one cell that did 103 not, a process known as polyclonal seeding. 104 To explore the epigenetic differences between malignant and benign H3.3-mutated

105 bone tumours we collected additional tumours for DNA methylation array analysis

106 (**Methods**). This collection (n = 121), included some of the sequenced samples,

107 osteosarcomas without H3.3 mutations, and chondroblastomas, a benign tumour

108 with an alternative H3.3 mutation, *H3F3B*:p.K27M (**Supplementary Table 2**).

109 Unsupervised clustering based on the most variable methylation probes

110 recapitulated the diagnostic groups (**Figure 2a and Supplementary Figure 7**).

111 Furthermore, while closely related to conventional GCTB, the malignant H3.3-mutant

112 tumours formed a distinct clade. The benign metastasising samples clustered with

113 the benign GCTB group.

114 To unpick the methylation differences underlying the separate clustering of the 115 benign and malignant H3.3 mutated tumours, differentially methylated regions 116 (DMRs) were identified. This revealed focal changes in a small number of specific 117 gene promoters (**Methods**). Of 74 DMRs identified, 56 were located around gene 118 transcriptions start sites (**Supplementary Figure 8**). The most statistically significant 119 DMR was also the only one identified in a plausible cancer driver gene, *CCND1,*  120 which encodes Cyclin D1. Differential methylation spanned a promoter region of

121 1500bp either side of the transcription start site, a finding validated by bisulfite 122 sequencing (**Supplementary Figure 9**). Comparing the mean methylation level 123 across this promoter region between different bone and soft tissue tumour types 124 revealed that hypermethylation at this site is specific to GCT (**Figure 2d**). Malignant 125 histone-mutated tumours and chondrosarcomas were the only tumour types with a 126 similar degree of *CCND1* promoter methylation. *CCND1* promoter methylation was 127 concordant with unsupervised methylation clustering groups (**Figure 1** and **Figure**  128 **2**). Beyond this, methylation differences were enriched at non-enhancer intergenic 129 sites, however those that affected genes did not consistently alter gene pathways. At 130 a broader scale part of the cluster of histone genes on chromosome 6 was focally 131 hypermethylated in malignant tumours, suggesting additional epigenetic driver 132 events (Supplementary **Figure 10**).

133 Using comprehensive genomic and methylation profiling, we report the driver events 134 associated with malignant or metastatic progression of GCTBs. Malignant H3.3 135 mutated tumours are characterized by a methylation profile that is related but distinct 136 from conventional GCTB. Histone mutation predates the development of aneuploidy 137 in malignant tumours, which still occurs some years prior to diagnosis. Malignant 138 progression requires additional genetic mutations endowing either telomere or 139 epigenetic dysfunction, and possible additional epigenetic changes altering clusters 140 of histone genes. This combination of genomic and epigenomic findings could 141 potentially distinguish benign from malignant GCTs, thereby predicting aggressive 142 behavior in challenging diagnostic cases (**Figure 1b** and **Supplementary Table 3**): it 143 also permits malignant GCTB to be classified on a molecular basis distinguishing it 144 from other primary malignant bone tumours. The absence of additional genetic 145 events in metastatic, but histologically benign GCTB, and the presence of polyclonal

 $\sim$  600  $\sim$ 

- 146 seeding supports the longstanding hypothesis that they represent a thrombotic
- 147 event.

#### 148 **Methods**

### 149 **Patient samples**

- 150 Patients provided their written and informed consent to provide samples for this
- 151 study via the UCL Biobank for Health and Disease, based at the Royal National
- 152 Orthopaedic Hospital. This was approved by the National Research Ethics Service
- 153 (NRES) Committee Yorkshire & The Humber Leeds East (15/YH/0311). DNA was
- 154 extracted from areas of fresh frozen tissue selected by bone pathologists
- 155 (A.M.F./R.T./F.A./P.E.). Matched normal DNA was acquired from blood samples.

#### 156 **SNP and Methylation Array**

- 157 SNP analysis was performed using the Illumina HumanOmni2.5 BeadChip. DNA
- 158 Methylation analysis was performed on either Illumina Infinium
- 159 HumanMethylation450 or MethylationEPIC arrays. Pre-processing and quality
- 160 control were performed (**Supplementary Methods**).

#### 161 **Array analysis**

- 162 SNP array copy number profiles were produced using ASCAT (v2.5.1). Methylation
- 163 array-based copy number profiles were generated using the conumee package
- 164 (v1.18.0) and a bespoke adaptation of the principles utilised by ASCAT
- 165 (**Supplementary Methods**). Unsupervised clustering was performed by hierarchical
- 166 clustering using the 5,000 most variable probes across samples after scrutiny for

167 batch effects (**Supplementary Methods**). Differentially methylated probes and 168 regions were detected using the ChAMP package (v2.14.0). Gene set enrichment 169 analysis (GSEA) was performed using an adapted approach from the ebBayes 170  $\pm$  function in the ChAMP package<sup>15</sup>. Bespoke analysis for regional differences in 171 methylation were performed using Circular Binary Segmentation (CBS) functions 172 from the DNACopy package (v1.58.0) based on a signal-noise ratio for each

173 methylation probe (**Supplementary Methods**).

#### 174 **Whole genome bisulfite sequencing**

- 175 Whole genome bisulfite sequencing was performed on seven of the samples:
- 176 PD30981a, PD30982a, PD30984a, PD30985a, PD3788d, PD3795d and PD4915d.
- 177 Oxidative bisulfite conversion and library preparation was done using the Cambridge
- 178 Epigenetix Truemethyl Whole Genome kit following manufacturer's instructions. The
- 179 efficiency of bisulfite treatment was determined using control probes; 90.6% of 5-
- 180 methylcytosine remaining unconverted and 100% of unmethylated cytosines were
- 181 converted into thymines. Hydroxymethylation was not detected using this kit as
- 182 91.7% of 5-hydroxymethyl cytosine were converted to thymine. Libraries were
- 183 sequenced on an llumina HiSeqX using a 150bp paired end run. Both mapping of
- 184 reads to GRCh37 and methylation calling was done using Bismark
- 185 (https://github.com/FelixKrueger/Bismark).

#### 186 **Whole genome sequencing**

- 187 For whole genome sequencing the Illumina (Illumina, Chesterford, UK) no-PCR
- 188 library protocol was used to construct short insert  $500$  bp libraries, prepare flowcells
- 189 and generate clusters. Whole genome sequencing was performed using the Illumina
- 190 HiSeq 2000 or 2500 platform, using 100 bp paired-end libraries. Samples PD37332,
- 191 PD3788, PD3795, PD38328, PD38329, PD4915, PD4922 were sequenced using the
- 192 XTen platform using 150 bp paired-end libraries.

#### 193 **Variant detection, validation and analysis**

- 194 The Cancer Genome Project (Wellcome Trust Sanger Institute) variant calling
- 195 pipeline was used to call somatic mutations (versions as below). All variant calling
- 196 algorithms were used with standard settings with limited post-processing filtering and
- 197 variants were analysed using a previously documented strategy<sup>9</sup> (**Supplementary**
- 198 **Methods**). Variants were considered as potential drivers if they presented in
- 199 established cancer genes (Chapter 3 COSMIC v82, Chapter 4 COSMIC v85).
- 200 Tumour suppressor coding variants were considered if they were annotated as
- 201 functionally deleterious by the VAGrENT algorithm
- 202 (http://cancerit.github.io/VAGrENT/). Disruptive rearrangements or homozygous
- 203 deletions of tumour suppressors were also considered. Additionally, homozygous
- 204 deletions were required to be focal  $\left\langle \langle 1 \rangle \right\rangle$  details and multiple in oncogenes were
- 205 considered driver events if they were located at previously reported hot spots (point
- 206 mutations) or amplified the intact gene. Amplifications also had to be focal  $\left($  < 1  $\Box$ Mb)
- 207 and result in at least 5 copies in diploid genomes, or 4 copies more than the modal
- 208 major copy number in genome duplicated samples.

#### 209 **Copy number scoring**

- 210 A sample was considered Whole Genome Duplicated (WGD) when the modal total 211 copy number was >2. The baseline total copy number was considered as 4 for WGD
- 212 samples and 2 for others. Autosomal copy number segments were then scored as

213 the difference from this baseline; no difference (0), total copy number of 0

- 214 (homozygous deletion, 2), total copy number  $>= 3 +$  baseline (amplification, 2), other
- 215 score not equal to baseline (1). Scores were normalised relative to the length of the
- 216 chromosome, summed and then divided by the theoretical maximum (44).
- 217 Aneuploidy was validated using image cytometry on nuclear extracts from formalin
- 218 fixed tissue sections (**Supplementary Methods**).

## 219 **Mutation clustering, phylogenetic reconstruction and timing analyses**

- 220 The algorithm DPClust (v2.2.6) and its pre-processing pipeline (v1.0.8) were used to
- 221 cluster mutations according to fraction of cancer cells (Cancer Cell Fraction, CCF) in
- 222 which they were found, as described previously<sup>20</sup> (**Supplementary Methods**).
- 223 Phylogenetic reconstruction was performed using the pigeon-hole principle<sup>20</sup>. In
- 224 brief, subclones were designated to be nested within a clone or another subclone if
- 225 their combined CCF exceeded that of their parent.
- 226 Initial timing analysis required the transformation of individual mutation allele
- 227 frequencies into mutation copy number. This was performed using the equation:

$$
MCN = \frac{VAF(\rho \times TCN + 2(1 - \rho))}{\rho}
$$

228 MCN is Mutation Copy Number,  $\rho$  is the sample purity, TCN is the local total copy 229 number.

- 230 For WGD timing, deamination (clock-like, C>T mutations at CpG dinucelotides)
- 231 mutations were selected from regions of balanced gain (2+2) or LOH (2+0). A
- 232 probabilistic approach to WGD timing was taken with confidence intervals generated

- 233 by bootstrapping sampling iterations of the underlying mutations (**Supplementary**
- 234 **Methods**).

235

### 236 **Data availability**

- 237 DKFZ raw methylation array data (IDAT files) were acquired from the authors of
- 238 Koelsche *et al*, the data having been acquired as described<sup>22</sup>.
- 239 The authors declare that all data supporting the findings of this study are available
- 240 within the article and its supplementary files or from the corresponding author on
- 241 reasonable request. Sequencing data have been deposited at the European
- 242 Genome-Phenome Archive (http://www.ebi.ac.uk/ega/) that is hosted by the
- 243 European Bioinformatics Institute.

# 244 **Acknowledgements**



# 269 **Author Contributions**

- 270 AMF conceived the project. M.W.F. performed the data analyses to which P.L., P.E,
- 271 I.L. and N.P. contributed some preliminary analyses. J.I. performed whole genome
- 272 bisulfite analysis. A-C.S. performed DNA extraction. D.O. contributed the image
- 273 cytometry analysis. A.M.F., P.E., R.T. and F.A. curated and reviewed the samples,
- 274 clinical data and/or provided clinical expertise. M.S., C.K., I.L. and D.T.W.J.
- 275 contributed to the methylation analyses. M.T. contributed to the methylation copy
- 276 number analysis and the timing analyses. J.D. contributed to discussions. A.M.F.,
- 277 P.V.L., and S.B. directed the research. M.W.F, P.V.L., S.B., and A.M.F. wrote the
- 278 manuscript.

## 279 **Competing interests**

280 The authors declare no competing financial or non-financial interests.

## 281 **Corresponding author**

282 Correspondence to Adrienne M Flanagan and Sam Behjati

## 284 **Figure Legends**

#### 285 **Figure 1. Landscape of H3.3 mutant tumours.** a) Mutational burden of

- 286 samples in comparison with selected other mesenchymal tumours: osteoblastoma<sup>23</sup>.
- 287 chondroblastoma<sup>5</sup>, chondrosarcoma<sup>24</sup> (\*exome data only; SVs not shown), and
- 288  $\degree$  osteosarcoma<sup>9</sup>. b) The genomic and methylation classification of sequenced
- 289 tumours. From top to bottom: clinical diagnoses and age, unsupervised methylation
- 290 cluster assignment, *CCND1* promoter methylation status (hypermethylation is
- 291 defined as a mean *CCND1* promoter methylation beta value >0.2 and a tileplot of
- 292 curated drivers, clinical outcomes are shown underneath (more detailed clinical
- 293 outcomes are shown in **Supplementary Table 1**). Note sample PD38328a had
- 294 undergone deletion of the H3F3A locus, which had been present on the pre-
- 295 resection biopsy (**Supplementary Figure 11**)

#### 296 **Figure 2. Methylation changes of H3.3 mutant tumours.**

297 a) Hierarchical (unrooted) clustering of tumours. Leaves are coloured by diagnosis

298 and the methylation clusters annotated with shaded ovals. b) Analysis of methylation

299 differences between malignant ("M") and benign ("G") tumours (n=12 and 40

300 respectively) across chromosome 11 (upper) and across *CCND1* (lower). Raw

301 (black) and segmented (green) signal-noise-ratio (SNR; >0 shows greater

302 methylation in malignant tumours) are plotted. Blue ticks in the upper plot represent

- 303 DMRs. In the lower plot raw methylation beta values across *CCND1* are shown for
- 304 each sample. The underlying schematic represents the *CCND1* gene body (grey)
- 305 and the predicted promoter (green). c) Mean *CCND1* promoter across the clustered
- 306 samples from a) and d) a variety of other tissues.

### **Supplementary Legends**

- **Supplementary Table 1. Clinical table of sequenced cases**
- **Supplementary Table 2. Clinical table for methylation and SNP array cases**
- **Supplementary Table 3. Clinically indeterminate cases**
- **Supplementary Figure 1. Telomere lengths and mutation burdens for**
- **sequenced tumours**
- **Supplementary Figure 2.** *TERT* **rearrangement in PD3788d**
- **Supplementary Figure 3.** *KDM4B* **homozygous deletion and** *RB1* **loss of**
- **heterozygosity**
- **Supplementary Figure 4. SNP and Methylation array-based copy number**
- **scores**
- **Supplementary Figure 5. Mutation timing in malignant samples**
- **Supplementary Figure 6. Mutation clustering in metastatic samples**
- **Supplementary Figure 7. Tumour methylation clustering with other malignant**
- **bone tumours**
- **Supplementary Figure 8. Selected gene promoters identified as differentially**
- **methylated regions**

# **Supplementary Figure 9. Whole genome bisulfite sequencing confirmation of**

- *CCND1* **differential methylation**
- **Supplementary Figure 10. Differential methylation in the HIST1 cluster**
- **Supplementary Figure 11. The loss of H3.3 mutation in sample PD38328a**

## 330 **References**

- 331 1. WHO Classisification of Soft Tissue and Bone Tumours (IARC Publications, 2020).
- 332 2. Presneau, N. et al. J Pathol Clin Res 1, 113-23 (2015).<br>333 3. Ogura, K. et al. Genes Chromosomes Cancer 56, 711-
- 333 3. Ogura, K. et al. Genes Chromosomes Cancer **56**, 711-718 (2017).<br>334 4. Amary, F. et al. Am J Sura Pathol **41**, 1059-1068 (2017).
- 334 4. Amary, F. et al. Am J Surg Pathol 41, 1059-1068 (2017).<br>335 5. Behiati. S. et al. Nat Genet 45, 1479-82 (2013).
- 335 5. Behjati, S. *et al. Nat Genet* 45, 1479-82 (2013).<br>336 6. Yamamoto. H. *et al. Hum Pathol 73*, 41-50 (201
- 336 6. Yamamoto, H. *et al. Hum Pathol 73, 41-50 (2018).*<br>337 7. Muheremu. A. & Niu. X. *World J Sura Oncol* 12, 26
- 337 7. Muheremu, A. & Niu, X. World J Surg Oncol 12, 261 (2014).<br>338 8. Bertoni. F.. Bacchini. P. & Staals. E.L. Cancer 97. 2520-9 (200
- 338 8. Bertoni, F., Bacchini, P. & Staals, E.L. Cancer **97**, 2520-9 (2003).<br>339 9. Behjati, S. *et al. Nat Commun* 8, 15936 (2017).
- 339 9. Behjati, S. et al. Nat Commun 8, 15936 (2017).<br>340 10. Horn, S. et al. Science 339, 959-61 (2013).
- 340 10. Horn, S. et al. Science **339**, 959-61 (2013).<br>341 11. Khan. A. & Zhang. X. *Nucleic Acids Res* 44.
- 341 11. Khan, A. & Zhang, X. *Nucleic Acids Res* **44**, D164-71 (2016).<br>342 12. Barthel, F.P. *et al. Nature Genetics* **49**, 349 (2017).
- 342 12. Barthel, F.P. *et al. Nature Genetics* 49, 349 (2017).<br>343 13. Bryan, T.M., Englezou, A., Dalla-Pozza, L., Dunham
- 343 13. Bryan, T.M., Englezou, A., Dalla-Pozza, L., Dunham, M.A. & Reddel, R.R. *Nature Medicine* 3,<br>344 1271-1274 (1997). <sup>344</sup>1271-1274 (1997).
- 345 14. PCAWG. Nature 578, 82-93 (2020).<br>346 15. Morris, T.J. et al. Bioinformatics 30,
- 346 15. Morris, T.J. et al. Bioinformatics 30, 428-30 (2014).<br>347 16. Li. H. & Durbin. R. Bioinformatics 25. 1754-60 (2009)
- 347 16. Li, H. & Durbin, R. *Bioinformatics* **25**, 1754-60 (2009).<br>348 17. Jones. D. *et al. Curr Protoc Bioinformatics* **56**. 15 10 1
- 348 17. Jones, D. et al. Curr Protoc Bioinformatics 56, 15 10 1-15 10 18 (2016).<br>349 18. Ye, K., Schulz, M.H., Long, Q., Apweiler, R. & Ning, Z. Bioinformatics 25
- 349 18. Ye, K., Schulz, M.H., Long, Q., Apweiler, R. & Ning, Z. Bioinformatics 25, 2865-71 (2009).<br>350 19. Dentro, S.C., Wedge, D.C. & Van Loo, P. *Cold Spring Harb Perspect Med 7* (2017).
- 350 19. Dentro, S.C., Wedge, D.C. & Van Loo, P. *Cold Spring Harb Perspect Med 7(2017).*<br>351 20. Nik-Zainal. S. *et al. Cell* 149. 994-1007 (2012).
- 351 20. Nik-Zainal, S. et al. Cell 149, 994-1007 (2012).<br>352 21. Ding, Z. et al. Nucleic Acids Research 42, e75-6
- 352 21. Ding, Z. et al. Nucleic Acids Research 42, e75-e75 (2014).<br>353 22. Koelsche. C. et al. Clin Sarcoma Res 7. 9 (2017).
- 353 22. Koelsche, C. *et al. Clin Sarcoma Res 1*, 9 (2017).<br>354 23. Fittall, M.W. *et al. Nat Commun* **9**, 2150 (2018).
- 354 23. Fittall, M.W. et al. Nat Commun 9, 2150 (2018).<br>355 24. Tarpey. P.S. et al. Nat Genet 45. 923-6 (2013).
- Tarpey, P.S. et al. Nat Genet 45, 923-6 (2013).



